Sumitomo Pharma Am Drug Patent Portfolio
Sumitomo Pharma Am owns 6 orange book drugs protected by 66 US patents with Gemtesa having the least patent protection, holding only 5 patents. And Kynmobi with maximum patent protection, holding 19 patents. Given below is the list of Sumitomo Pharma Am's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12357636 | 04 May, 2042 | Active | |
| US12102638 | Use of vibegron to treat overactive bladder | 22 Mar, 2040 | Active |
| US11793812 | Methods of treating endometriosis | 03 May, 2038 | Active |
| US11033551 | Methods of treating uterine fibroids | 29 Sep, 2037 | Active |
| US11957684 | Treatment of heavy menstrual bleeding associated with uterine fibroids | 29 Sep, 2037 | Active |
| US10449191 | Treatment of prostate cancer | 29 Sep, 2037 | Active |
| US10786501 | Treatment of prostate cancer | 29 Sep, 2037 | Active |
| US11583526 | Treatment of prostate cancer | 29 Sep, 2037 | Active |
| US12097198 | Treatment of prostate cancer | 29 Sep, 2037 | Active |
| US12144809 | Treatment of prostate cancer | 29 Sep, 2037 | Active |
| US12336990 | Treatment of prostate cancer | 29 Sep, 2037 | Active |
| US10744277 | Aerosol delivery device and method of operating the aerosol delivery device | 07 Dec, 2036 | Active |
| US10688518 | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator | 12 Nov, 2036 | Active |
| US10449146 | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | 19 Apr, 2036 | Active |
| US10959943 | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa | 19 Apr, 2036 | Active |
| US10350170 | Solid preparation | 25 Feb, 2036 | Active |
| US10376661 | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element | 14 Sep, 2035 | Active |
| US12180219 | Process for preparing beta 3 agonists and intermediates | 12 Mar, 2034 | Active |
| US11795178 | Compositions of thienopyrimidine derivatives | 27 Sep, 2033 | Active |
| US12325714 | Compositions of thienopyrimidine derivatives | 27 Sep, 2033 | Active |
| US9604018 | Aerosol therapy device | 16 May, 2033 | Active |
| US9168556 | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer | 01 Sep, 2032 | Active |
| US9750747 | Treatments involving eslicarbazepine acetate or eslicarbazepine | 24 Aug, 2032 | Active |
| US11419769 | Sublingual films | 16 Dec, 2031 | Active |
| US8414922 | Sublingual films | 16 Dec, 2031 | Active |
| US8846074 | Sublingual films | 16 Dec, 2031 | Active |
| US8247415 | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists | 01 Dec, 2030 | Active |
| US9789270 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized | 30 Oct, 2030 | Active |
| US10420763 | Sublingual apomorphine | 11 Jun, 2030 | Active |
| US9044475 | Sublingual apomorphine | 11 Jun, 2030 | Active |
| US9283219 | Sublingual films | 11 Jun, 2030 | Active |
| US9326981 | Sublingual apomorphine | 11 Jun, 2030 | Active |
| US9669019 | Sublingual apomorphine | 11 Jun, 2030 | Active |
| US9669021 | Sublingual apomorphine | 11 Jun, 2030 | Active |
| US8372431 | Pharmaceutical composition comprising licarbazepine acetate | 17 Apr, 2030 | Active |
| US10821074 | Sublingual and buccal film compositions | 07 Aug, 2029 | Active |
| US8653260 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | 02 Apr, 2029 | Active |
| US10940110 | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations | 26 Feb, 2029 | Active |
| US9265900 | Disposable ampoule for an aerosol generating device | 07 Dec, 2028 | Active |
| US10912781 | Pharmaceutical composition comprising licarbazepine acetate | 23 Oct, 2028 | Active |
| US9566244 | Pharmaceutical composition comprising licarbazepine acetate | 23 Oct, 2028 | Active |
| US9763954 | Therapeutical uses of eslicarbazepine | 13 Sep, 2028 | Active |
| US11278683 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized | 16 Aug, 2026 | Active |
| US9206135 | Asymmetric catalytic reduction of oxcarbazepine | 21 Apr, 2026 | Active |
| US9643929 | Asymmetric catalytic reduction of oxcarbazepine | 21 Apr, 2026 | Active |
| US7300935 | Thienopyrimidine compounds and use thereof | 28 Jan, 2026 | Active |
| US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof | 28 Jan, 2026 | Active |
| US7931212 | Fluid droplet production apparatus and method | 25 Nov, 2025 | Active |
| US10675287 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | 06 May, 2025 | Expired |
| US10695354 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | 06 May, 2025 | Expired |
| US10702536 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | 06 May, 2025 | Expired |
| US11364247 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | 06 May, 2025 | Expired |
| US7458372 | Inhalation therapy device | 18 Nov, 2024 | Expired |
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions | 03 Apr, 2024 | Expired |
| US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | 20 Feb, 2024 | Expired |
| US9346822 | Thienopyrimidine compounds and use thereof | 17 Feb, 2024 | Expired |
| US8735401 | Thienopyrimidine compounds and use thereof | 04 Feb, 2024 | Expired |
| US8511581 | Fluid droplet production apparatus and method | 08 Nov, 2023 | Expired |
| US8663687 | Film compositions for delivery of actives | 02 Feb, 2023 | Expired |
| US7316067 | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step | 06 Sep, 2022 | Expired |
| US10888499 | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom | 14 Feb, 2022 | Expired |
| US11077068 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | 14 Feb, 2022 | Expired |
| US9855221 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | 14 Feb, 2022 | Expired |
| US9931305 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions | 14 Feb, 2022 | Expired |
| US5753646 | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them | 27 Jun, 2021 | Expired |
| US6962151 | Inhalation nebulizer | 27 Oct, 2020 | Expired |
Latest Legal Activities on Sumitomo Pharma Am's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sumitomo Pharma Am.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent eCertificate of Correction | 09 Jul, 2024 | US10786501 |
|
Email Notification
Critical
| 09 Jul, 2024 | US10786501 |
| Mail Patent eCofC Notification | 09 Jul, 2024 | US10786501 |
| Patent eCofC Notification | 09 Jul, 2024 | US10786501 |
| Mail Certificate of Correction Memo | 02 Jul, 2024 | US10449191 |
| Mail Certificate of Correction Memo | 02 Jul, 2024 | US11583526 |
| Post Issue Communication - Certificate of Correction | 01 Jul, 2024 | US10449191 |
| Post Issue Communication - Certificate of Correction | 01 Jul, 2024 | US11583526 |
| Certificate of Correction Memo | 30 Jun, 2024 | US10449191 |
| Certificate of Correction Memo | 30 Jun, 2024 | US11583526 |
| Post Issue Communication - Certificate of Correction | 17 Jun, 2024 | US10786501 |
| Mail Certificate of Correction Memo | 12 Jun, 2024 | US10786501 |
| Certificate of Correction Memo | 07 Jun, 2024 | US10786501 |
|
Email Notification
Critical
| 17 Apr, 2024 | US11957684 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 16 Apr, 2024 | US11957684 |
Sumitomo Pharma Am's Drug Patent Litigations
Sumitomo Pharma Am's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 28, 2014, against patent number US8765167. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with MonoSol Rx, LLC. et al. as the respondent. Click below to track the latest information on how companies are challenging Sumitomo Pharma Am's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8603514 | June, 2017 |
Institution Denied
(20 Oct, 2017)
| MonoSol Rx, LLC et al. | Par Pharmaceutical, Inc. et al. |
| US8603514 | June, 2017 |
Terminated-Denied
(20 Oct, 2017)
| MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | June, 2017 |
Institution Denied
(20 Oct, 2017)
| MonoSol Rx, LLC et al. | Dr. Reddy’s Laboratories, Inc. et al. |
| US8603514 | June, 2017 |
Terminated-Denied
(20 Oct, 2017)
| MonoSol Rx, LLC | Par Pharmaceutical, Inc. |
| US8603514 | November, 2016 |
Terminated-Settled
(06 Oct, 2017)
| MonoSol Rx, LLC et al. | Mylan Technologies, Inc. et al. |
| US8603514 | May, 2016 |
Terminated-Denied
(05 Dec, 2016)
| MonoSol Rx, LLC | Dr. Reddy's Laboratories, Inc. |
| US8603514 | May, 2016 |
Institution Denied
(05 Dec, 2016)
| MonoSol Rx, LLC et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US8603514 | December, 2015 |
Institution Denied
(23 May, 2016)
| MONOSOL RX LLC et al. | Teva Pharmaceuticals USA Inc |
| US8603514 | December, 2015 |
Terminated-Denied
(23 May, 2016)
| MONOSOL RX LLC | Teva Pharmaceuticals USA Inc |
| US8765167 | October, 2014 |
Final Written Decision
(24 Mar, 2016)
| MonoSol Rx, LLC. et al. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
FWD Entered
(24 Mar, 2016)
| MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Terminated-Settled
(24 Mar, 2016)
| MonoSol Rx, LLC. et al. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Terminated-Denied
(20 May, 2015)
| MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Institution Denied
(20 May, 2015)
| MonoSol Rx, LLC. et al. | BioDelivery Sciences International, Inc. |
Sumitomo Pharma Am Drug Patents' Oppositions Filed in EPO
Sumitomo Pharma Am drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 11, 2012, by Lts Lohmann Therapie-Systeme Ag. This opposition was filed on patent number EP02801042A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP17823018A | Dec, 2022 | SANDOZ AG | Granted and Under Opposition |
| EP14815314A | Feb, 2021 | Vectura Limited | Opposition rejected |
| EP15175258A | May, 2019 | D Young & Co LLP | Granted and Under Opposition |
| EP08842368A | Jun, 2017 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Opposition rejected |
| EP08705172A | Jun, 2017 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP08705172A | Jun, 2017 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Revoked |
| EP10786915A | May, 2016 | LTS LOHMANN Therapie-Systeme AG | Granted and Under Opposition |
| EP10786915A | May, 2016 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP11157819A | Jun, 2014 | Ahrens, Gabriele | Patent maintained as amended |
| EP02782151A | Jun, 2013 | Acino Pharma AG | Revoked |
| EP02782151A | Jun, 2013 | Germann, Sandra | Revoked |
| EP02801042A | Sep, 2012 | Ahrens, Gabriele | Patent maintained as amended |
| EP02801042A | Sep, 2012 | LTS LOHMANN Therapie-Systeme AG | Patent maintained as amended |
Sumitomo Pharma Am's Family Patents
Sumitomo Pharma Am drugs have patent protection in a total of 52 countries. It's US patent count contributes only to 30.9% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Sumitomo Pharma Am Drug List
Given below is the complete list of Sumitomo Pharma Am's drugs and the patents protecting them.
1. Aptiom
Aptiom is protected by 12 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9750747 | Treatments involving eslicarbazepine acetate or eslicarbazepine |
24 Aug, 2032
(6 years from now)
| Active |
| US8372431 | Pharmaceutical composition comprising licarbazepine acetate |
17 Apr, 2030
(4 years from now)
| Active |
| US10912781 | Pharmaceutical composition comprising licarbazepine acetate |
23 Oct, 2028
(2 years from now)
| Active |
| US9566244 | Pharmaceutical composition comprising licarbazepine acetate |
23 Oct, 2028
(2 years from now)
| Active |
| US9763954 | Therapeutical uses of eslicarbazepine |
13 Sep, 2028
(2 years from now)
| Active |
| US9206135 | Asymmetric catalytic reduction of oxcarbazepine |
21 Apr, 2026
(5 months from now)
| Active |
| US9643929 | Asymmetric catalytic reduction of oxcarbazepine |
21 Apr, 2026
(5 months from now)
| Active |
| US10675287 | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
06 May, 2025
(5 months ago)
| Expired |
| US10695354 | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
06 May, 2025
(5 months ago)
| Expired |
| US10702536 | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
06 May, 2025
(5 months ago)
| Expired |
| US11364247 | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
06 May, 2025
(5 months ago)
| Expired |
| US5753646 | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
27 Jun, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aptiom's drug page
2. Gemtesa
Gemtesa is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12357636 |
04 May, 2042
(16 years from now)
| Active | |
| US12102638 | Use of vibegron to treat overactive bladder |
22 Mar, 2040
(14 years from now)
| Active |
| US12180219 | Process for preparing beta 3 agonists and intermediates |
12 Mar, 2034
(8 years from now)
| Active |
| US8247415 | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
01 Dec, 2030
(5 years from now)
| Active |
| US8653260 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
02 Apr, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gemtesa's drug page
3. Kynmobi
Kynmobi is protected by 19 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10449146 | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
19 Apr, 2036
(10 years from now)
| Active |
| US10959943 | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa |
19 Apr, 2036
(10 years from now)
| Active |
| US11419769 | Sublingual films |
16 Dec, 2031
(6 years from now)
| Active |
| US8414922 | Sublingual films |
16 Dec, 2031
(6 years from now)
| Active |
| US8846074 | Sublingual films |
16 Dec, 2031
(6 years from now)
| Active |
| US10420763 | Sublingual apomorphine |
11 Jun, 2030
(4 years from now)
| Active |
| US9044475 | Sublingual apomorphine |
11 Jun, 2030
(4 years from now)
| Active |
| US9283219 | Sublingual films |
11 Jun, 2030
(4 years from now)
| Active |
| US9326981 | Sublingual apomorphine |
11 Jun, 2030
(4 years from now)
| Active |
| US9669019 | Sublingual apomorphine |
11 Jun, 2030
(4 years from now)
| Active |
| US9669021 | Sublingual apomorphine |
11 Jun, 2030
(4 years from now)
| Active |
| US10821074 | Sublingual and buccal film compositions |
07 Aug, 2029
(3 years from now)
| Active |
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
03 Apr, 2024
(1 year, 6 months ago)
| Expired |
| US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
20 Feb, 2024
(1 year, 8 months ago)
| Expired |
| US8663687 | Film compositions for delivery of actives |
02 Feb, 2023
(2 years ago)
| Expired |
| US10888499 | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
14 Feb, 2022
(3 years ago)
| Expired |
| US11077068 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
14 Feb, 2022
(3 years ago)
| Expired |
| US9855221 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
14 Feb, 2022
(3 years ago)
| Expired |
| US9931305 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
14 Feb, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kynmobi's drug page
4. Lonhala Magnair Kit
Lonhala Magnair Kit is protected by 14 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10744277 | Aerosol delivery device and method of operating the aerosol delivery device |
07 Dec, 2036
(11 years from now)
| Active |
| US10688518 | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator |
12 Nov, 2036
(11 years from now)
| Active |
| US10376661 | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element |
14 Sep, 2035
(9 years from now)
| Active |
| US9604018 | Aerosol therapy device |
16 May, 2033
(7 years from now)
| Active |
| US9168556 | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer |
01 Sep, 2032
(6 years from now)
| Active |
| US9789270 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
30 Oct, 2030
(5 years from now)
| Active |
| US10940110 | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations |
26 Feb, 2029
(3 years from now)
| Active |
| US9265900 | Disposable ampoule for an aerosol generating device |
07 Dec, 2028
(3 years from now)
| Active |
| US11278683 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
16 Aug, 2026
(9 months from now)
| Active |
| US7931212 | Fluid droplet production apparatus and method |
25 Nov, 2025
(30 days from now)
| Active |
| US7458372 | Inhalation therapy device |
18 Nov, 2024
(11 months ago)
| Expired |
| US8511581 | Fluid droplet production apparatus and method |
08 Nov, 2023
(1 year, 11 months ago)
| Expired |
| US7316067 | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step |
06 Sep, 2022
(3 years ago)
| Expired |
| US6962151 | Inhalation nebulizer |
27 Oct, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lonhala Magnair Kit's drug page
5. Myfembree
Myfembree is protected by 8 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11793812 | Methods of treating endometriosis |
03 May, 2038
(12 years from now)
| Active |
| US11033551 | Methods of treating uterine fibroids |
29 Sep, 2037
(11 years from now)
| Active |
| US11957684 | Treatment of heavy menstrual bleeding associated with uterine fibroids |
29 Sep, 2037
(11 years from now)
| Active |
| US11795178 | Compositions of thienopyrimidine derivatives |
27 Sep, 2033
(7 years from now)
| Active |
| US12325714 | Compositions of thienopyrimidine derivatives |
27 Sep, 2033
(7 years from now)
| Active |
| US7300935 | Thienopyrimidine compounds and use thereof |
28 Jan, 2026
(3 months from now)
| Active |
| US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
28 Jan, 2026
(3 months from now)
| Active |
| US9346822 | Thienopyrimidine compounds and use thereof |
17 Feb, 2024
(1 year, 8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myfembree's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Orgovyx
Orgovyx is protected by 12 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10449191 | Treatment of prostate cancer |
29 Sep, 2037
(11 years from now)
| Active |
| US10786501 | Treatment of prostate cancer |
29 Sep, 2037
(11 years from now)
| Active |
| US11583526 | Treatment of prostate cancer |
29 Sep, 2037
(11 years from now)
| Active |
| US12097198 | Treatment of prostate cancer |
29 Sep, 2037
(11 years from now)
| Active |
| US12144809 | Treatment of prostate cancer |
29 Sep, 2037
(11 years from now)
| Active |
| US12336990 | Treatment of prostate cancer |
29 Sep, 2037
(11 years from now)
| Active |
| US10350170 | Solid preparation |
25 Feb, 2036
(10 years from now)
| Active |
| US11795178 | Compositions of thienopyrimidine derivatives |
27 Sep, 2033
(7 years from now)
| Active |
| US12325714 | Compositions of thienopyrimidine derivatives |
27 Sep, 2033
(7 years from now)
| Active |
| US7300935 | Thienopyrimidine compounds and use thereof |
28 Jan, 2026
(3 months from now)
| Active |
| US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
28 Jan, 2026
(3 months from now)
| Active |
| US8735401 | Thienopyrimidine compounds and use thereof |
04 Feb, 2024
(1 year, 8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orgovyx's drug page